Brivaracetam

SV2A binding drug which exhibits it antiepileptic activity by blocking voltage sensitive neuronal Na channels (proposed mechanism).

FDA status: Approved on February 2016

Company: UCB, Inc

Drugs<>Therapeutics<>Big Pharma
impas Natesh Prabhu Administrator & Chief Editor | Clinical Pharmacologist | Diabetic-Sexual Medicine-Regenerative Therapy Consultant | President, Indian Medical Pharmacologists Association
0

Leave a Reply

↓